3. Spinal muscular atrophy Clinical trials / Disease details

Clinical trials : 237 / Drugs : 123 - (DrugBank : 29) / Drug target genes : 51 - Drug target pathways : 75

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00439569 (ClinicalTrials.gov)	January 2008	21/2/2007	Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Types II or III	Phase I/IIa Clinical Trial of Sodium Phenylbutyrate in Pediatric Subjects With Type II/III Spinal Muscular Atrophy	Spinal Muscular Atrophy Type II;Spinal Muscular Atrophy Type III	Drug: sodium phenylbutyrate	Westat	National Institute of Neurological Disorders and Stroke (NINDS)	Terminated	2 Years	11 Years	All	9	Phase 1/Phase 2	United States
2	NCT00439218 (ClinicalTrials.gov)	January 2008	22/2/2007	Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Type I	Phase I/IIa Clinical Trial of Sodium Phenylbutyrate in Pediatric Subjects With Type I Spinal Muscular Atrophy	Spinal Muscular Atrophy Type I	Drug: sodium phenylbutyrate	Westat	National Institute of Neurological Disorders and Stroke (NINDS)	Terminated	2 Months	48 Months	All	5	Phase 1/Phase 2	United States
3	NCT00528268 (ClinicalTrials.gov)	July 2007	10/9/2007	Study to Evaluate Sodium Phenylbutyrate in Pre-symptomatic Infants With Spinal Muscular Atrophy	Prospective Phase I/II Study to Evaluate Effects of Sodium Phenylbutyrate in Pre-symptomatic Infants With Spinal Muscular Atrophy	Spinal Muscular Atrophy	Drug: Sodium phenylbutyrate (NaPB)	University of Utah	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Completed	N/A	6 Months	All	14	Phase 1/Phase 2	United States